Physician profile
Thomas K Tan
NPI 1447328620
$25,930.46
in general payments reported to CMS, 2019-2025
37 companies · $5,313 in 2025
The $5,313 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,929 · 2020: $3,799 · 2021: $3,894 · 2022: $2,933 · 2023: $3,146 · 2024: $3,916 · 2025: $5,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $38.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,337.49 |
| Education | $38.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $4,019.65 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,989.67 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,514.92 | 2019-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $2,463.16 | 2022-2025 | |
| Lilly USA, LLC | $2,162.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,774.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,548.87 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $1,187.78 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $649.27 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $646.27 | 2019-2022 | |
| Gilead Sciences, INC. | $578.25 | 2023-2025 | Vemlidy |
| Corcept Therapeutics | $542.73 | 2022-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $366.19 | 2019-2022 | |
| Abbvie INC. | $315.16 | 2019-2025 | |
| Genentech USA, INC. | $308.75 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $278.94 | 2025 | Freestyle Libre 3 |
| Insulet Corporation | $275.00 | 2025 | Omnipod |
| Dexcom, INC. | $271.53 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Arbor Pharmaceuticals, INC. | $266.88 | 2019-2020 | |
| Horizon Therapeutics Plc | $202.84 | 2019-2023 | Tepezza, Krystexxa |
| Novartis Pharmaceuticals Corporation | $197.78 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $182.84 | 2025 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $162.65 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $159.02 | 2019-2025 | Verquvo, Capvaxive, M-M-R II |
| Csl Behring | $149.25 | 2025 | Andembry |
| Nestle Healthcare Nutrition INC. | $124.27 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $121.99 | 2021 | |
| Esperion Therapeutics, INC. | $98.42 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $88.24 | 2019 | |
| Vifor Pharma, INC. | $59.22 | 2020-2024 | Zemaira |
| Medtronic, INC. | $59.20 | 2022-2025 | Inceptiv |
| Regeneron Healthcare Solutions, INC. | $44.63 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $37.31 | 2020-2021 | |
| Radius Health, INC. | $26.71 | 2019 | |
| Leo Pharma INC. | $19.88 | 2021 | |
| Boston Scientific Corporation | $18.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.